Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant cisplatin + vinorelbine vs gemcitabine + vinorelbine in resected NSCLC
2008-000570-21Phase 2Active
- Sponsor
- Innovative Sensor Technology IST AG
- Start
- Nov 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in non-small cell lung cancer (NSCLC) comparing cisplatin + vinorelbine with gemcitabine + vinorelbine (2 arms). Primary endpoint: Tolerability (drug delivery and toxicity). Started Nov 2008; status: active.
02
Drugs
cisplatingemcitabinevinorelbine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2008-000570-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000570-21.